WO2012170839A3 - Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1 - Google Patents

Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1 Download PDF

Info

Publication number
WO2012170839A3
WO2012170839A3 PCT/US2012/041586 US2012041586W WO2012170839A3 WO 2012170839 A3 WO2012170839 A3 WO 2012170839A3 US 2012041586 W US2012041586 W US 2012041586W WO 2012170839 A3 WO2012170839 A3 WO 2012170839A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neuroinflammatory disease
selective cox1
cox1 inhibitors
inhibitors
Prior art date
Application number
PCT/US2012/041586
Other languages
English (en)
Other versions
WO2012170839A2 (fr
Inventor
Karen J. Brunke
John CAUFIELD
Keni NII
Makoto OHMIYA
Original Assignee
Cardeus Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardeus Pharmaceuticals, Inc., Astellas Pharma, Inc. filed Critical Cardeus Pharmaceuticals, Inc.
Publication of WO2012170839A2 publication Critical patent/WO2012170839A2/fr
Publication of WO2012170839A3 publication Critical patent/WO2012170839A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des inhibiteurs hautement sélectifs de COX1 pouvant être utilisés pour traiter une maladie neuro-inflammatoire.
PCT/US2012/041586 2011-06-09 2012-06-08 Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1 WO2012170839A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161495267P 2011-06-09 2011-06-09
US61/495,267 2011-06-09
US201161502657P 2011-06-29 2011-06-29
US61/502,657 2011-06-29

Publications (2)

Publication Number Publication Date
WO2012170839A2 WO2012170839A2 (fr) 2012-12-13
WO2012170839A3 true WO2012170839A3 (fr) 2013-02-21

Family

ID=47296765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041586 WO2012170839A2 (fr) 2011-06-09 2012-06-08 Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1

Country Status (1)

Country Link
WO (1) WO2012170839A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300048B2 (en) * 2014-05-28 2019-05-28 Universitat Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191155A1 (en) * 2001-11-09 2003-10-09 Satoshi Aoki Triazole derivatives
US6803380B1 (en) * 1999-11-09 2004-10-12 Laboratoire Theramex 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
US20100022540A1 (en) * 2006-05-18 2010-01-28 Hans-Michael Eggenweiler Triazole derivatives ii
US20110034504A1 (en) * 2008-04-01 2011-02-10 Astellas Pharma Inc. Agent for preventing and/or treating vascular diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803380B1 (en) * 1999-11-09 2004-10-12 Laboratoire Theramex 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
US20030191155A1 (en) * 2001-11-09 2003-10-09 Satoshi Aoki Triazole derivatives
US20100022540A1 (en) * 2006-05-18 2010-01-28 Hans-Michael Eggenweiler Triazole derivatives ii
US20110034504A1 (en) * 2008-04-01 2011-02-10 Astellas Pharma Inc. Agent for preventing and/or treating vascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNKO IMANISHE ET AL.: "Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor", BIOCHEMICAL PHARMACOLOGY, vol. 82, no. 7, 2 July 2011 (2011-07-02), pages 746 - 754 *

Also Published As

Publication number Publication date
WO2012170839A2 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
EP2788376A4 (fr) Anticorps neutralisants dirigés contre le vih-1 et leur utilisation
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
AP3849A (en) Use of inhibitors of the activity or function of pi3k
WO2012145254A9 (fr) Procédés d'utilisation d'inhibiteurs de rorϒt pour traiter une maladie
BR112015002681A2 (pt) método para tratar um paciente e kit
BR112014009785A2 (pt) método para tratar ou reduzir efp
IL230433A0 (en) Pain management methods
ZA201308459B (en) A topical formulation for treatment of hyperkeratotic skin
IL228719A0 (en) parp inhibitors for the treatment of cipn
HK1255668A1 (zh) 用於治療皮膚病症的包含二吲哚基甲烷和類視黃醇的組合物
ZA201403739B (en) Methods of treatment with deferiprone
EP2720695A4 (fr) Agents et méthodes de traitement de maladies ischémiques et d'autres maladies
EP2688901A4 (fr) Inhibiteurs de 17ss-hsd1, 17ss-hsd3 et 17ss-hsd10
RS58381B1 (sr) Lečenje zavisnosti i poremećaja kontrole impulsa upotrebom pde7 inhibitora
WO2012170839A3 (fr) Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
HK1208373A1 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors pde7
EP2722050A4 (fr) Utilisation de l'huile d'olive dans la prévention et le traitement des maladies associées à un processus ischémique
AU2016201537A1 (en) Methods for chronic pain management and treatment using hcg
AU2011905428A0 (en) Treatment of Hydrocarbons
AU2012905402A0 (en) A method of treatment and agents useful for same
AU2012902036A0 (en) A method of treatment and agents useful for same
AU2012900480A0 (en) A method of treatment and agents useful for same
AU2011902655A0 (en) Methods of treating or preventing rheumatic disease
AU2011900528A0 (en) New Concept Dog Treat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12796451

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014514887

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12796451

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP